BioSpace News Archive

Business

Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2022

In the first calendar quarter of 2022, Utah Medical Products, Inc. attained financial results consistent with achieving its goals for calendar year 2022.

April 26, 2022
·
14 min read
Business

NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center

NexImmune, Inc. today announced a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert Irving Comprehensive Cancer Center (HICCC).

April 26, 2022
·
4 min read
Biotech Bay

Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York

Corvus Pharmaceuticals, Inc. today announced that it will host an R&D Symposium to provide an update on the Company’s three clinical programs. The event will be held on Tuesday, May 10, 2022, in New York City from 9:00 – 11:30 am Eastern Time.

April 26, 2022
·
1 min read
Pharm Country

Antios Therapeutics Announces Notice of Allowance for U.S. Patent on Phosphoramidates for the Treatment of Hepatitis B Virus

Antios Therapeutics, Inc today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 16/312,756.

April 26, 2022
·
3 min read
Drug Development

BioEclipse Therapeutics™ Awarded Almost $8 Million Grant by California Institute for Regenerative Medicine (CIRM) to Fund Ongoing Phase 1 CRX100 Cancer Immunotherapy Clinical Trial

BioEclipse Therapeutics announced today it has been awarded a $7,999,689.00 grant by the California Institute for Regenerative Medicine (CIRM) to support its ongoing clinical study: A Phase 1, open-label, dose-escalation study of CRX100 in patients with advanced solid tumors.

April 26, 2022
·
3 min read
Drug Development

Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).

April 26, 2022
·
4 min read
Business

Rubius Therapeutics to Announce First Quarter 2022 Financial Results

Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced plans to report first quarter financial results on Tuesday, May 10, 2022, before market open.

April 26, 2022
·
1 min read
Drug Development

SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has dosed the first patient in its Phase1/2 CLAUDIO-01 trial of SOT102 in patients with gastric and pancreatic cancer.

April 26, 2022
·
3 min read
Drug Development

OncoC4 Announces Fast Track Designation Granted by the U.S. FDA for ONC-392 Monotherapy in PD(L)1-Resistant NSCLCA Phase 1b clinical trial of ONC-392 in PD(L)1-resistant NSCLC is currently underway

OncoC4, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ONC-392, as a single agent for the treatment of patients with metastatic non-small cell lung carcinoma (NSCLC) who have had disease progression on prior anti-PD-(L)1 therapy.

April 26, 2022
·
4 min read
Business

Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022

Talis Biomedical Corporation announced that it will report first quarter financial results on Tuesday, May 10, 2022, after market close.

April 26, 2022
·
1 min read